Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Provided By GlobeNewswire
Last update: Mar 21, 2025
Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.
Read more at globenewswire.comNASDAQ:SLXN (6/5/2025, 10:33:09 AM)
0.9314
-0.02 (-1.95%)
Find more stocks in the Stock Screener
SLXN Latest News and Analysis
3 days ago - ChartmillThese stocks that are showing activity before the opening bell on Monday.The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
6 days ago - ChartmillFriday's after hours session: top gainers and losersWondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
10 days ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
